. Author manuscript; available in PMC: 2021 Dec 1.

Published in final edited form as: Cancer Chemother Pharmacol. 2020 Oct 23;86(6):829–840. doi: 10.1007/s00280-020-04171-4

Table 4.

Treatment responses including prolonged stable disease

Tumor Histology	Part of Study	Crizotinib dose (mg/m²/dose)	Response	Prior exposure to cytotoxic agents received
Ewing Sarcoma	A	165	PR	YES
Primitive neuroectodermal tumor (PNET)	A	165	Prolonged SD (8 cycles)	NO
PNET/Ewing Sarcoma Family	A	165	CR	NO
Neuroblastoma	B	165	CR	YES
Epithelial-myoepithelial carcinoma	B	215	PR	Unknown
Osteosarcoma	C	215	PR	NO
Renal cell carcinoma	C	280	PR	NO
Ewing Sarcoma	C	165	PR	NO
Neuroblastoma	D	165	Prolonged SD (10 cycles)	YES
Undifferentiated sarcoma	D	215	Prolonged SD (6 cycles)	NO